Pharming Group N.V. announces that its Chief Executive Officer, Sijmen de Vries, will present at the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid meeting based in New York, at the Lotte Palace Hotel, September 12-14, 2022.

Pharming announces that its Chief Executive Officer, Sijmen de Vries, will present at the Jefferies Healthcare Conference 2022, a hybrid meeting based in New York, at 22:00-22:30 CET/16:00-16:30 EDT on 9 June 2022.

Pharming Group announces new data from the pivotal Phase II/III trial of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a primary immunodeficiency.

Pharming announces that Principal Investigator V. Koneti Rao, MD, FRCPA, a staff physician in the Primary Immune Deficiency Clinic at the National Institutes of Health in Bethesda, Maryland, will present positive findings from the Phase III pivotal clinical trial of leniolisib for patients with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) at the Clinical Immunology Society (CIS) 2022 Annual Meeting in Charlotte, North Carolina.

Pharming Group N.V. today announces that its Chief Executive Officer, Sijmen de Vries, will present at the 31st Annual Oppenheimer Healthcare Conference 2021 at 15:40-16:10 CET/10:40-11:10 EDT on 16 March 2021.

Pharming Group today announces that its Chief Executive Officer, Sijmen de Vries, will present at BioCapital Europe 2021 at 10:30 CET on 11 March 2021

Call slides now available for download.

CEO of Pharming Sijmen de Vries presented at the 21st Annual Global Life Science Investment Conference on the 9th of September in New York City.